Key result
This protocol outlines a planned multicenter cohort study of 150 patients to evaluate whether immune cell characteristics predict 1-year major adverse cardiovascular events in acute coronary syndrome.
Why the study?
Immune responses play a vital role in ACS, but their specific relationship to its occurrence and progression requires further definition.
Cohort (n=150)
Yes
Answers are grounded in this paper and cite their sources.
This study protocol outlines a prospective cohort study to investigate the prognostic value of immune cell characteristics and specific surface markers (CD47, sirpα, S100A4, Tim-3) in predicting 1-year MACE in patients with acute coronary syndrome.
BACKGROUND: Acute coronary syndrome(ACS) is the leading cause of mortality and disability worldwide. Immune response has been confirmed to play a vital role in the occurrence and development of ACS. The objective of this prospective, multicenter, observational study is to define immune response and their relationship to the occurrence and progressive of ACS. METHODS: This is a multicenter, prospective, observational longitudinal cohort study. The primary outcome is the incidence of major adverse cardiovascular events (MACE) including in-stent restenosis, severe ventricular arrhythmia, heart failure, recurrent angina pectoris, and sudden cardiac death, and stroke one year later after ACS. Demographic characteristics, clinical data, treatments, and outcomes are collected by local investigators. Furthermore, freshly processed samples will be stained and assessed by flow cytometry. The expression of S100A4, CD47, SIRPα and Tim-3 on monocytes, macrophages and T cells in ACS patients were collected. FOLLOW-UP: during hospitalization, 3, 6 and 12 months after discharge. DISCUSSION: It is expected that this study will reveal the possible targets to improve the prognosis or prevent from occurrence of MACE in ACS patients. Since it's a multicenter study, the enrollment rate of participants will be accelerated and it can ensure that the collected data are more symbolic and improve the richness and credibility of the test basis. ETHICS AND DISSEMINATION: This study has been registered in Chinese Clinical Trial Registry Center. Ethical approval was obtained from the Affiliated Hospital of Guizhou Medical University. The dissemination will occur through the publication of articles in international peer-reviewed journals. TRIAL REGISTRATION: Chinese Clinical Trial Registry: ChiCTR2200066382.
No takes yet. Share an insight, caveat, or question.
Lin et al. (2023) conducted a cohort in Acute coronary syndrome (n=150). Immune cell characteristics (monocytes, macrophages, T cells, CD47, sirpα, Tim-3, S100A4) was evaluated on Major adverse cardiovascular events (MACE) within 1 year. This protocol outlines a planned multicenter cohort study of 150 patients to evaluate whether immune cell characteristics predict 1-year major adverse cardiovascular events in acute coronary syndrome.
Synapse has enriched 10 related papers. Consider them for comparative context: